A pathophysiology diagram titled 'Impact of hypertension on viral immunity' comparing cellular immune responses under normal and hypertensive conditions. The top panel, 'Normal blood pressure,' illustrates a dendritic cell presenting antigens to a T cell via receptor-ligand interactions and cytokine release. This stimulation leads to robust T-cell activation and proliferation, resulting in a large cluster of effector T cells essential for viral clearance. The bottom panel, 'Hypertension,' depicts the same initial dendritic cell-T cell interaction but highlights the presence of elevated Angiotensin II. Angiotensin II binds to Angiotensin II receptors expressed on the activated T cell. This signaling inhibits sustained proliferation and instead promotes a T-cell contraction phase, resulting in a significantly reduced population of T cells. The diagram indicates that this hypertensive state leads to an impaired effector response and delayed viral clearance. Key components labeled include dendritic cells, T cells, cytokines, Angiotensin II, and Angiotensin II receptors.

This pathophysiology diagram illustrates the anti-hypertensive mechanism of Lactiplantibacillus plantarum (Lb. plantarum) in functional foods. The process begins with Lb. plantarum fermenting milk, which produces bioactive hydrolysates. These hydrolysates function as Angiotensin-Converting Enzyme (ACE) inhibitors, targeting the zinc-binding (Zn2+) site of the ACE protein. The diagram depicts two physiological pathways influenced by this inhibition: 1) The Bradykinin Pathway: Typically, ACE degrades the vasodilator bradykinin into inactive products. By inhibiting ACE, hydrolysates prevent bradykinin degradation, promoting vasodilation and relieving hypertension. 2) The Renin-Angiotensin Pathway: Normally, ACE transforms Angiotensin I into the potent vasoconstrictor Angiotensin II, leading to vascular contraction and hypertension. The hydrolysates inhibit this transformation, preventing pathological vasoconstriction. The visual contrast emphasizes the transition from constricted, hypertensive blood vessel states to relaxed, dilated states through the modulation of enzymatic activity. This diagram serves as a model for how probiotic-derived peptides can mitigate cardiovascular risk factors by interfering with the biochemical pathways responsible for systemic blood pressure regulation.

An anatomical and pathophysiology diagram illustrating the brain regions and neural pathways involved in neurogenic hypertension. The illustration features a sagittal view of the human brain with key regulatory centers labeled, including the hypothalamus, paraventricular nucleus (PVN), and components of the brainstem: the rostral ventrolateral medulla (RVLM), nucleus of the solitary tract (NTS), caudal ventrolateral medulla (CVLM), and the intermediolateral cell column (IML). Purple stars denote the locations of circumventricular organs (CVOs) distributed near the hypothalamus and brainstem. The diagram maps the functional connectivity between these regions and the heart. A green line represents the parasympathetic input originating from the RVLM/brainstem area, while a red line represents the sympathetic input originating from the IML, both descending to the cardiac target. This illustration highlights the neuroregulatory network responsible for blood pressure control and the autonomic imbalance (increased sympathetic and decreased parasympathetic tone) characteristic of neurogenic hypertension.

This pathophysiology diagram illustrates the mechanism of action of imidazoline receptor agonists on blood pressure regulation. The visual is divided into a sagittal brain anatomical diagram and a secondary physiological flowchart. On the left, the diagram highlights the 'I1 imidazoline receptors' located within the Rostral Ventrolateral Medulla (RVLM) of the brainstem, situated inferior to the cerebrum and anterior to the cerebellum. Below this, three pharmacological agents—Clonidine, Moxonidine, and Rilmenidine—are listed as imidazole agonists that target these receptors. To the right, a downward flowchart depicts the systemic consequences of receptor activation: stimulation of the RVLM leads to the 'Inhibition of sympathetic nerve activity,' followed by the 'Inhibition of norepinephrine' release. This progression results in 'Decreased vasoconstriction,' visually represented by an illustration of a dilated blood vessel with reduced smooth muscle tension. The final clinical outcome is identified as 'Reduced blood pressure.' The content is designed for intermediate medical education, focusing on neuropharmacology and cardiovascular physiology.

Summary : This figure illustrates the organ-specific and vascular effects of hypertension, detailing pathological changes in the eye, heart, kidney, brain, large and medium arteries, and microcirculation. Each organ system is listed with its associated hypertensive complications. diagram: # Organ Systems and Hypertensive Effects : ## Eye : • Microvascular remodelling • Hypertensive retinopathy ## Heart : • LVH (left ventricular hypertrophy) • LA and LV dilatation (left atrial and left ventricular) • AF (atrial fibrillation) • Obstructive and non-obstructive CAD (coronary artery disease) • Myocardial infarction • Diastolic and/or systolic heart failure ## Kidney : • Glomerular arteriolar hypertension • Glomerulosclerosis • Albuminuria/Proteinuria • ↓ GFR (glomerular filtration rate) ## Brain : • White matter lesions • Silent microinfarcts • Microbleeds • Brain atrophy • Cognitive impairment • Vascular dementia • Ischaemic stroke • Cerebral haemorrhage ## Large and Medium Arteries : • Atherosclerosis • Vascular calcification • Arterial stiffness ## Microcirculation : • Endothelial dysfunction • ↑ Vasoreactivity • Vascular remodelling • Fibrosis and inflammation • ↑ Peripheral vascular resistance # Layout : • Central human figure with icons representing each organ system. • Each organ system is connected to a text box listing its hypertensive complications. • Colour-coded circles and boxes for each organ/vascular system. # Additional Information : • Footnote mentions sex-differences (not detailed in the figure). • ESC (European Society of Cardiology) logo at the bottom right. # Analysis : • The figure demonstrates that hypertension affects multiple organ systems, with distinct pathological changes in each. • Both macrovascular (large arteries) and microvascular (small vessels, microcirculation) complications are highlighted. • The heart, brain, and kidney are shown to be particularly vulnerable, with a wide range of structural and functional consequences. • The diagram visually emphasises the systemic nature of hypertensive disease and its multi-organ impact.

Summary : This figure presents a flowchart for the management of comorbidities associated with Heart Failure with Preserved Ejection Fraction (HFpEF), detailing recommended strategies for atrial fibrillation, hypertension, coronary artery disease, type 2 diabetes, chronic kidney disease, sleep apnea, and obesity. flowchart: # Nodes : • HFpEF Comorbidities (central header, rectangle) • Atrial fibrillation (rectangle) – Rate vs rhythm control strategy guided by symptoms (avoid aggressive rate control due to low stroke volume) – BB or nondihydropyridine CCB + digoxin if needed – Anticoagulation unless contraindicated • Hypertension (rectangle) – BP <130/80 mm Hg (higher goal in patients with symptomatic orthostasis) – Diuretic agent, ARNI, ARB, MRA – Evaluate for secondary causes when appropriate • Coronary artery disease (rectangle) – Testing and intervention guided by presentation and symptoms – Medical management as per relevant guidelines • Type 2 diabetes (rectangle) – Target HbA1c <7-7.5% – SGLT2i first-line – GLP-1 RAs if obesity or high risk for ASCVD – Avoid alogliptin, saxagliptin, thiazolidinediones • Chronic kidney disease (rectangle) – RAAS inhibitors and SGLT2is may slow progression of renal disease – ARNI if eGFR ≥30 mL/min/1.73m² – SGLT2i if eGFR ≥20 mL/min/1.73m² • Sleep apnea (rectangle, below hypertension/coronary artery disease) – Symptoms and risk factors → polysomnography – Referral to sleep specialist for OSA – Weight loss • Obesity (rectangle, below type 2 diabetes/chronic kidney disease) – Weight loss → improved hemodynamics, functional status, and quality of life – Exercise, calorie restriction – Semaglutide or tirzepatide # Connectors : • Central node “HFpEF Comorbidities” branches to five main comorbidity nodes (atrial fibrillation, hypertension, coronary artery disease, type 2 diabetes, chronic kidney disease) in a horizontal row. • Sleep apnea and obesity nodes are placed below and connected to the main row, indicating additional comorbidities. • No explicit decision diamonds; all nodes are rectangles with bulleted management strategies. # Layout : • Horizontal top row: five main comorbidity nodes. • Central header above. • Two additional comorbidity nodes (sleep apnea, obesity) below the main row. • All nodes contain bulleted lists of management recommendations. # Analysis : • The flowchart provides a comprehensive, organized approach to managing common comorbidities in HFpEF, emphasizing tailored strategies for each condition. • There is a focus on evidence-based pharmacologic and non-pharmacologic interventions, with specific drug classes and targets listed for each comorbidity. • The inclusion of sleep apnea and obesity highlights the importance of addressing lifestyle and secondary risk factors in HFpEF management. • The structure allows clinicians to quickly reference recommended actions for each comorbidity, supporting integrated care.

CHA₂DS₂-VASc	Congestive heart failure, Hypertension, Age ≥75 years (2 points), Diabetes mellitus, Stroke or transient ischaemic attack (2 points), Vascular disease, Age 65–74 years, Sex category (female)	EDIC
		eGFR
		ELIXA
CHAP	Chronic Hypertension and Pregnancy
CHD	Coronary heart disease	EMMY
CI	Confidence interval
CKD	Chronic kidney disease
CKD-EPI	Chronic kidney disease epidemiology/CKD Epidemiology Collaboration	EMPA-KIDNEY
CKD-MBD	Chronic kidney disease–mineral bone disorder	EMPA-REG
CLEAR	Cholesterol Lowering via Bempedoic Acid, an ACL-Inhibiting Regimen	OUTCOME
		EMPA-RESPONSE
CLTI	Chronic limb-threatening ischaemia	AHF
COMPASS	Cardiovascular Outcomes for People Using Anticoagulation Strategies	EMPEROR-Preserved
CPG	Clinical Practice Guidelines
CREDENCE	Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation	EMPEROR-Reduced
CRT	Cardiac resynchronization therapy
CRT-D	Cardiac resynchronization therapy with an implantable defibrillator	EMPULSE
CRT-P	Cardiac resynchronization therapy-pacemaker
CT	Computed tomography	EORP
CTA	Computed tomography angiography	ER
CURRENT-OASIS	Clopidogrel Optimal Loading Dose Usage to Reduce Recurrent EveNTs/Optimal Antiplatelet Strategy for InterventionS	ESC
		ESH
		EXAMINE
CV	Cardiovascular
CVD	Cardiovascular disease
CVOT	Cardiovascular outcomes trial	EXSCEL
DAPA-CKD	Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease	FIDELIO-DKD
DAPA-HF	Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure
DAPT	Dual antiplatelet therapy	FIGARO-DKD
DAT	Dual antithrombotic therapy
DBP	Diastolic blood pressure
DCCT	Diabetes Control and Complications Trial	FLOW
DD	Double diabetes
DECLARE-TIMI 58	Dapagliflozin Effect on Cardiovascular Events –Thrombolysis In Myocardial Infarction 58
DELIVER	Dapagliflozin Evaluation to Improve the Lives of Patients with Preserved Ejection Fraction Heart Failure	FOURIER
DES	Drug-eluting stent	FPG
DEVOTE	A Trial Comparing Cardiovascular Safety of Insulin Degludec vs Insulin Glargine in Patients With Type 2 Diabetes at High Risk of Cardiovascular Events	GDM
		GFR
		GLOBAL-LEADERS
DIAL	Diabetes lifetime-perspective prediction
DIGAMI	Diabetes Mellitus Insulin-Glucose Infusion in Acute Myocardial Infarction	GLP-1 RA
		GRACE
DiRECT	Diabetes Remission Clinical Trial	HARMONY
DPP-4	Dipeptidyl peptidase-4	Outcomes
EACTS	European Association for Cardio-Thoracic Surgery
EASD	European Association for the Study of Diabetes	HAS-BLED
ECG	Electrocardiogram
EDC	Pittsburgh Epidemiology of Diabetes Complications

Clinical photography of a generalized morbilliform drug eruption on the skin illustrating an exanthematous eruption due to fosinopril, an ACE inhibitor prescribed for hypertension. The image depicts numerous erythematous macules and papules, some coalescing into diffuse patches on the trunk and proximal limbs, including the exposed upper arm. Lesions are blanching on pressure, non-vesicular, slightly raised, and pruritic in many patients. There is no mucosal involvement evident in this view. Morphology is stereotypical for a morbilliform eruption: symmetric distribution, rapid onset after drug exposure, and a proximal-to-distal spread pattern. The clinical context supports a cutaneous adverse drug reaction triggered by fosinopril, with timing typically 5–14 days after initiation or dose escalation, consistent with a type IV hypersensitivity mechanism. Diagnostic significance lies in recognizing drug-induced exanthem to prevent progression, guide drug withdrawal, and prompt substitution with an alternative antihypertensive (e.g., an ARB). Differential diagnoses include viral exanthem, allergic contact dermatitis, and pityriasis rosea; clinical correlation with medication history is essential. If biopsy is performed, histology would commonly show superficial perivascular lymphocytic infiltrate with eosinophils and mild spongiosis. This image is useful for clinical education, pharmacovigilance, and dermatology training on ACE inhibitor–related rashes and drug eruption management. Prompt action improves patient outcomes.

Summary : This figure presents a clinical guideline recommendation for first-line antihypertensive drug therapy in adults, including the class of recommendation (COR) and level of evidence (LOE). table: COR & LOE : • COR: 1 (Class of Recommendation 1, indicating strong recommendation). • LOE: A (Level of Evidence A, indicating high-quality evidence). Recommendation : • For adults initiating antihypertensive drug therapy, the following are recommended as first-line therapy to prevent cardiovascular disease (CVD): – Thiazide-type diuretics – Long-acting dihydropyridine calcium channel blockers (CCB) – Angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB) • Recommendation is supported by references 1 and 2. Analysis : • The figure provides a clear, evidence-based recommendation for initial antihypertensive therapy, prioritizing specific drug classes based on strong evidence for CVD prevention. • The use of COR 1 and LOE A signals that these recommendations are both strongly endorsed and supported by robust clinical data.

This diagnostic image displays the Fourier-transform infrared (FTIR) spectra used in pharmaceutical research for drug delivery systems. The chart compares the chemical fingerprints of Manidipine (MAN), a third-generation calcium channel blocker used for hypertension, and poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHBV), a biodegradable polymer used for microencapsulation. The x-axis represents the wavenumber in cm⁻¹ (ranging from 4000 to 400), while the y-axis shows transmittance. The MAN spectrum reveals characteristic peaks at 3345 cm⁻¹ (N-H stretching) and 1721 cm⁻¹ (C=O stretching). The PHBV and microparticle formulation spectra (PHBV-M0, M5, M10) demonstrate a dominant carbonyl peak at approximately 1725 cm⁻¹. The comparison between the physical mixture (MAN + PHBV) and the microparticle formulations is used to evaluate drug-polymer interactions and the successful incorporation of the antihypertensive agent into the porous polymer matrix, which is clinically relevant for developing sustained-release medications.